Virus

City of Hope Launches First-of-its-Kind Mobile Cancer Prevention and Screening Program

Retrieved on: 
Monday, February 26, 2024
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Hospitals, Health Technology, Other Health, American Cancer Society, Music, NCI, Multimedia, Education, Cancer, National Cancer Institute, AV, Volunteering, Risk, Death, Practitioner, Vaccine, Virus, Risk assessment, Nursing, Organization, Human resources, Policy, Genetic testing, Patient, Health equity, Research, Entertainment, Mobile phone

City of Hope, one of the largest cancer research and treatment organizations in the United States, is taking leading-edge clinical screening and care into Southern California communities and beyond with the launch of their new mobile cancer prevention and screening program.

Key Points: 
  • City of Hope, one of the largest cancer research and treatment organizations in the United States, is taking leading-edge clinical screening and care into Southern California communities and beyond with the launch of their new mobile cancer prevention and screening program.
  • Cancer screening programs like City of Hope’s can help prevent thousands of additional cancer cases and deaths through early detection.
  • "Our comprehensive mobile cancer prevention and screening program is the next step in our mission to expand access to optimal cancer care, bringing our expertise outside the walls of our campus and into the communities we serve,” said Harlan Levine, president of Health Innovation and Policy at City of Hope.
  • While City of Hope’s mobile cancer prevention and screening program will initially launch in Southern California, the organization has plans to expand these offerings into additional communities of their other City of Hope cancer center locations.

Intertrend Creates Toyota’s First-Ever Anime Content Series

Retrieved on: 
Monday, February 26, 2024
General Automotive, Men, Social Media, Entertainment, Online, Family, Consumer, Automotive, Teens, Marketing, Children, Advertising, Communications, Women, Strategy, AAPI, Virus

Intertrend Communications , a culture-forward creative advertising agency known for helping leading U.S. brands better understand and reach Asian American audiences, today announces the launch of Toyota’s first-ever original anime content series , “GRIP.” This new adrenaline-fueled campaign premieres today and features Toyota’s Gazoo Racing (GR) series of cars as the hero, using authentic Japanese anime illustrations as a storytelling technique.

Key Points: 
  • Intertrend Communications , a culture-forward creative advertising agency known for helping leading U.S. brands better understand and reach Asian American audiences, today announces the launch of Toyota’s first-ever original anime content series , “GRIP.” This new adrenaline-fueled campaign premieres today and features Toyota’s Gazoo Racing (GR) series of cars as the hero, using authentic Japanese anime illustrations as a storytelling technique.
  • The five-episode content series, created by Intertrend, Executive Producer Frank Mele and Supervising Director Jae Woo Kim , is a high-octane anime adventure that combines heart-pounding action and a battle between the human spirit and computer control.
  • Airing weekly, each episode is one minute in length with the finale running slightly longer at one minute and 10 seconds.
  • The ‘GRIP’ content series showcases all that’s exciting about performance-oriented GR cars, while telling a thrilling story that we know will resonate with younger consumers.”
    To access the “GRIP” series, downloadable campaign assets and a variety of other GR-powered content, please visit www.toyota.com/grip .

Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024

Retrieved on: 
Monday, February 26, 2024
Biotechnology, FDA, AIDS, Health, Pharmaceutical, Research, Infectious Diseases, Hospitals, Science, COVID-19, Clinical Trials, Senior, Hepatitis B, CROI, Hook effect, RWE, STR, Viral, Virus, DTG, Mortality, Lenacapavir, Hepatitis, HBV, Vesatolimod, Fungal infection, HIV-1, MDR, PWH, HDV, Boxed warning, European, Islatravir, Tablet, European Commission, Liver disease, Omicron, Conference, Safety, ART, Civil service commission, Abstract, Bictegravir, Natural history, Virology, Emtricitabine, Gilead Sciences, MD, Food, Coinfection, Immunodeficiency, European Economic Area, Risk, Prevalence, Dexamethasone, Patient, Tuberculosis, INSIGHT, HIV, Pharmaceutical industry

Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir.

Key Points: 
  • Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir.
  • Additionally, a late-breaker oral presentation of Week 24 data from the INSIGHT trial evaluating Biktarvy in people with HIV and tuberculosis will be presented.
  • Gilead will present new data evaluating the safety and efficacy of Hepcludex® (bulevirtide) in people living with the coinfections of HIV, hepatitis B (HBV) and hepatitis delta (HDV).
  • Biktarvy combines the novel, unboosted INSTI bictegravir, with the Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, F/TAF) backbone.

Global Central Vacuum System Market Outlook, 2023-2024 and 2029: Key Opportunities Driven by Growth in Demand for CVS with Hepa Filters and Smart Vaccum Systems - ResearchAndMarkets.com

Retrieved on: 
Friday, February 23, 2024
Retail, Home Goods, Filtration, MERS, Dust, USD, Sanitation, Disinfectant, Coronavirus, Suction, Health, Growth, Noise, HEPA, SARS, Perception, Prevalence, Bacteria, Power, Virus, COVID, Vacuum, Car, Pollen, Hygiene

The global central vacuum systems market is highly competitive, with many vendors.

Key Points: 
  • The global central vacuum systems market is highly competitive, with many vendors.
  • Some of the major players dominating the global central vacuum systems market include Trovac, DrainVac, Nuera Air, Nilfisk Group, and Busch.
  • In Europe, the demand for central vacuum systems is experiencing an increase, driven by stringent hygiene standards in the food processing industry and concerns about air quality, and dominated the global central vacuum systems market share, accounting for over 38% in 2023.
  • Furthermore, the growth of central vacuum systems in the APAC is attributed to the APAC's expansion of manufacturing and metalworking facilities.

Synexis® LLC. Introduces Sentry XL, Expanding Indoor Environmental Quality Solutions

Retrieved on: 
Wednesday, March 6, 2024
Hydrogen, Oxygen, XL, Atmosphere, Temperature, Sentry, Volatile organic compound, Aluminium, DHP, Bacteria, Virus, Humidity, LED, Reinsurance

LENEXA, Kan., March 6, 2024 /PRNewswire/ -- Synexis is excited to introduce the Sentry XL, our latest product designed to offer exceptional performance and expanded coverage, transforming the way we experience living and working in larger occupied spaces.

Key Points: 
  • The Sentry XL joins the Synexis portfolio of Indoor Environmental Quality (IEQ) devices using a patented and advanced technology to continuously combat harmful pathogens in the air and on surfaces.
  • "We are excited to introduce the Sentry XL as the latest addition to our expanding product portfolio.
  • Key Features of the Sentry XL:
    Maximum Coverage: Effectively safeguards indoor areas of up to 3,000 square feet.
  • Robust Design: Crafted from high-quality materials, the Sentry XL is housed in a stainless-steel and aluminum frame, ensuring durability and reliability in challenging indoor conditions.

SEKISUI Diagnostics Receives Emergency Use Authorization for the OSOM® Flu SARS-CoV-2 Combo Test

Retrieved on: 
Tuesday, March 5, 2024
Urinary tract infection, Marketing, Clinical research, HHS, Health, COVID-19, Virus, COVID, Business administration

BURLINGTON, Mass., March 5, 2024 /PRNewswire/ -- SEKISUI Diagnostics, a global medical diagnostics manufacturer, has received EUA clearance for the OSOM Flu SARS-CoV-2 Combo Test for use in professional and home testing settings.

Key Points: 
  • BURLINGTON, Mass., March 5, 2024 /PRNewswire/ -- SEKISUI Diagnostics, a global medical diagnostics manufacturer, has received EUA clearance for the OSOM Flu SARS-CoV-2 Combo Test for use in professional and home testing settings.
  • The OSOM® Flu SARS-CoV-2 Combo Test is a lateral flow immunochromatographic assay intended for in vitro rapid, simultaneous qualitative detection and differentiation of influenza A and influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen.
  • As with other OSOM Rapid Tests, it is made in the USA and supported by a highly skilled technical support team of medical technologists/professionals.
  • "The utility of detecting COVID and Flu on one test is now more important than ever having moved into the endemic phase of COVID.

Datasea Expects Approximately 1,128% Revenue Growth in 2024

Retrieved on: 
Tuesday, March 5, 2024
Acoustics, Natural language processing, Algorithm, Infection, Artificial intelligence, AI, Coronavirus, Internet of things, Sound, RNA, Virus, Proton, Machine learning, Movement, NLP

BEIJING, March 5, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a Nevada corporation engaged in innovative business segments for Acoustics Intelligence and 5G-AI multimodal communication technology in China and the US, issued guidance today for expecting a revenue of approximately $86.0 million for the Company's full year ended June 30, 2024.

Key Points: 
  • BEIJING, March 5, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a Nevada corporation engaged in innovative business segments for Acoustics Intelligence and 5G-AI multimodal communication technology in China and the US, issued guidance today for expecting a revenue of approximately $86.0 million for the Company's full year ended June 30, 2024.
  • This represents approximately a 1,128% increase from revenue of $7.0 million which was reported for fiscal year ended June 30, 2023.
  • Datasea's CEO Zhixin Liu commented, "Our guidance of approximately $86.0 million in revenue is due to projected strong results from both of our business segments.
  • Our operating model encompasses distinct customer bases and sources of revenue which we believe will create long-term value for our shareholders."

Zymo Research Pioneers a Breakthrough in Large-scale Animal-free RNase A Production

Retrieved on: 
Tuesday, March 5, 2024
Ribonuclease, RNA, Prion, Research, Biotechnology, Virus, Failure, DNA, Risk, Vaccine

This breakthrough will enable the widespread use of recombinant RNase A in applications where an animal-free enzyme is preferred.

Key Points: 
  • This breakthrough will enable the widespread use of recombinant RNase A in applications where an animal-free enzyme is preferred.
  • Recognizing these challenges, Zymo Research has developed PureRec RNase A, an animal-free recombinant RNase A.
  • PureRec RNase A was developed and manufactured in Zymo Research's state-of-the-art facility in California, empowered by specialized expertise and advanced fermentation and bioprocessing technologies.
  • For more information or bulk inquiries on Zymo Research's recombinant RNase A, please check out PureRec RNase A .

Zymo Research Pioneers a Breakthrough in Large-scale Animal-free RNase A Production

Retrieved on: 
Tuesday, March 5, 2024
Ribonuclease, RNA, Prion, Research, Biotechnology, Virus, Failure, DNA, Risk, Vaccine

This breakthrough will enable the widespread use of recombinant RNase A in applications where an animal-free enzyme is preferred.

Key Points: 
  • This breakthrough will enable the widespread use of recombinant RNase A in applications where an animal-free enzyme is preferred.
  • RNase A is a critical enzyme extensively utilized in plasmid and genomic DNA purification processes due to its efficacy in degrading RNA contaminants.
  • Recognizing these challenges, Zymo Research has developed PureRec RNase A, an animal-free recombinant RNase A.
  • For more information or bulk inquiries on Zymo Research's recombinant RNase A, please check out PureRec RNase A .

Tampa General Hospital Brings New Hope for Patients with Advanced Blood Cancers

Retrieved on: 
Monday, March 4, 2024
Bone marrow, Blood pressure, Liver, Multiple myeloma, EVP, B-cell lymphoma, Immunotherapy, NHL, Borrello, Temperature, FDA, Physician, Food, Cancer, Hospital, Heart rate, Tampa General Hospital, Cell, Skin, Cancer Institute, B cell, BMT, Ear, Breast, Home, Safety, Bacteria, Johns Hopkins, APRN, Virus, TGH, Leukemia, Non-Hodgkin lymphoma, Patient, Lymphoma, Protein, Tampa, Florida, Medicine, Otorhinolaryngology, Nose, DLBCL, Immune system, Pharmaceutical industry

TAMPA, Fla., March 4, 2024 /PRNewswire/ -- As part of its commitment to harness innovative advances in cancer care, the Tampa General Hospital (TGH) Cancer Institute has added a novel approach to its therapeutic armamentarium for the treatment of patients with aggressive forms of B-cell non-Hodgkin lymphomas and other types of blood cancers.

Key Points: 
  • The field of immunotherapy has evolved from an academic research program to an essential pillar in the treatment of many cancers.
  • All are intended for the treatment of blood cancers, including lymphomas, some forms of leukemia and, most recently, multiple myeloma.
  • Following comprehensive planning and discussion, Tampa General's Hospital at Home program has started to be applied to CAR T patients meeting certain criteria.
  • Due the benefit of remote monitoring, the TGH Cancer Institute and Hospital at Home teams have been working on adapting Hospital at Home for oncology patients.